Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

236 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effectiveness, safety and reasons for discontinuation of sonidegib for patients with locally advanced basal cell carcinoma: A real-word evidence analysis from the French national registry CARADERM.
Basset-Seguin N, Djermane M, Herms F, Dalac S, Dereure O, Beylot-Barry M, Amini-Adle M, Minart B, Granel-Brocard F, Meyer N, Jouary T, Dreno B, Mortier L; Caraderm investigators. Basset-Seguin N, et al. J Eur Acad Dermatol Venereol. 2024 Dec 16. doi: 10.1111/jdv.20496. Online ahead of print. J Eur Acad Dermatol Venereol. 2024. PMID: 39676714 No abstract available.
Follow-Up of Patients With Complete Remission of Locally Advanced Basal Cell Carcinoma After Vismodegib Discontinuation: A Multicenter French Study of 116 Patients.
Herms F, Lambert J, Grob JJ, Haudebourg L, Bagot M, Dalac S, Dutriaux C, Guillot B, Jeudy G, Mateus C, Monestier S, Mortier L, Poulalhon N, Prey S, Robert C, Vabres P, Lebbe C, Meyer N, Basset-Seguin N. Herms F, et al. J Clin Oncol. 2019 Dec 1;37(34):3275-3282. doi: 10.1200/JCO.18.00794. Epub 2019 Oct 14. J Clin Oncol. 2019. PMID: 31609670
Emerging drugs for the treatment of basal cell carcinoma.
Herms F, Basset-Seguin N. Herms F, et al. Expert Opin Emerg Drugs. 2021 Mar;26(1):17-26. doi: 10.1080/14728214.2021.1873949. Epub 2021 Jan 24. Expert Opin Emerg Drugs. 2021. PMID: 33412913 Review.
Efficacy of sonic hedgehog inhibitors rechallenge, after initial complete response in recurrent advanced basal cell carcinoma: a retrospective study from the CARADERM database.
Bassompierre A, Dalac S, Dreno B, Neidhardt EM, Maubec E, Capelle C, Andre F, Behal H, Dziwniel V, Bens G, Leccia MT, Meyer N, Granel-Brocard F, Beylot-Barry M, Dereure O, Basset-Seguin N, Mortier L. Bassompierre A, et al. ESMO Open. 2021 Dec;6(6):100284. doi: 10.1016/j.esmoop.2021.100284. Epub 2021 Oct 21. ESMO Open. 2021. PMID: 34689002 Free PMC article.
Defining and recognising locally advanced basal cell carcinoma.
Amici JM, Battistella M, Beylot-Barry M, Chatellier A, Dalac-Ra S, Dreno B, Falandry C, Froget N, Giacchero D, Grob JJ, Guerreschir P, Leccia MT, Malard O, Mortier L, Routier E, Stefan A, Stefan D, Stoebner PE, Basset-Seguin N. Amici JM, et al. Eur J Dermatol. 2015 Nov-Dec;25(6):586-94. doi: 10.1684/ejd.2015.2641. Eur J Dermatol. 2015. PMID: 26574792 Review.
Topical methyl aminolevulinate photodynamic therapy for management of basal cell carcinomas in patients with basal cell nevus syndrome improves patient's satisfaction and reduces the need for surgical procedures.
Pauwels C, Mazereeuw-Hautier J, Basset-Seguin N, Livideanu C, Viraben R, Paul C, Meyer N. Pauwels C, et al. J Eur Acad Dermatol Venereol. 2011 Jul;25(7):861-4. doi: 10.1111/j.1468-3083.2010.03854.x. Epub 2010 Oct 3. J Eur Acad Dermatol Venereol. 2011. PMID: 21668511
Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial.
Basset-Seguin N, Hauschild A, Grob JJ, Kunstfeld R, Dréno B, Mortier L, Ascierto PA, Licitra L, Dutriaux C, Thomas L, Jouary T, Meyer N, Guillot B, Dummer R, Fife K, Ernst DS, Williams S, Fittipaldo A, Xynos I, Hansson J. Basset-Seguin N, et al. Lancet Oncol. 2015 Jun;16(6):729-36. doi: 10.1016/S1470-2045(15)70198-1. Epub 2015 May 13. Lancet Oncol. 2015. PMID: 25981813 Clinical Trial.
236 results